Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Moderna ( MRNA) reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday. Moderna's stock was down 4.5% in pre-market trading on the earnings ...

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...

Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...